

MEDIA RELEASE • COMMUNIQUE AUX MEDIAS • MEDIENMITTEILUNG

Novartis South Africa Makes New Leadership Appointments

Novartis South Africa welcomes Nico Bosch as Pharma Country Head and Shelley Horner as Oncology General Manager

Novartis South Africa has appointed Nico Bosch as **Pharma Country Head for South Africa** and Shelley Horner as **Country President South Africa**, in addition to her role as **Oncology General Manager South Africa & Sub-Saharan Africa**.

Bosch has 22 years of cross-functional experience in various roles within marketing and sales operations, market research, sales and marketing in the pharmaceutical industry.

He has been with Novartis since 2012 and was Franchise Director for Primary Care, before this appointment. Bosch also served as National Sales Manager Primary Care and Portfolio Manager, Cardiovascular and Metabolism in his previous roles at Novartis. Along with his extensive experience, Nico holds qualifications in Information Technology and Leadership Development.

Bosch adds: "I am grateful and honoured for this opportunity to lead Novartis' South Africa Pharma operations on our journey to reach more patients. I believe the success of Novartis lies in the number of patients whose lives we are able to extend and improve." He started his new role on February 1, 2020,

In relation to Shelley Horner's appointment, she has more than 30 years professional experience, having worked for different pharma companies including Janssen, Lilly and Merck KGaA holding multiple management positions. She had the unique opportunity to work across all franchises in the Novartis Pharma business, building up to her role as Oncology General Manager.

During her career at Novartis, Horner has built a strong Oncology team, championing some of the organization's ground-breaking initiatives across the Sub Sahara Africa region.

Horner has been ad interim South Africa Country President since December 2018 and has already made significant impact through her involvement in Industry associations such as IPASA.

“Collaboration is a key factor in implementing transformational healthcare systems in any society. No single organization can do this alone and as Novartis we are committed to playing our part in shaping the healthcare system in South Africa. This appointment has come at a time when multiple stakeholder engagement is required more than ever before to win for South Africa’s patients,” said Horner.

She will assume her new role immediately.

ENDS

About Novartis South Africa

Novartis South Africa focuses its business on three divisions with innovation power and global scale: pharmaceuticals, eye care and generics. These three divisions are supported by our research organization, the Novartis Institutes for BioMedical Research (NIBR), and a centralized services group, Novartis Business Services, to facilitate collaboration across our divisions, and drive efficiency and productivity gains.

For more information, visit: <https://www.novartis.co.za/>

About Novartis

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 105 000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com.

Novartis is on Facebook and Twitter. Sign up to follow @Novartis at

<https://www.facebook.com/novartis> or <http://twitter.com/novartis>

For Novartis multimedia content, please visit www.novartis.com/news/media-library

For questions about the site or required registration, please contact media.relations@novartis.com

###

Novartis Media Relations

Central media line: +41 61 324 2200

E-mail: media.relations@novartis.com

Sibonile Dube

Novartis Head of Communications and Public Affairs

+27 66 473 8113 (mobile)

sibonile.dube@novartis.com

[Eric Althoff](#)

[Novartis US External Communications](#)

[+1 646 438 4335](#)

eric.althoff@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central

Samir Shah +41 61 324 7944

Pierre-Michel Bringer +41 61 324 1065

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188

North America

Richard Pulik +1 862 778 3275

Cory Twining +1 862 778 3258

